2025 Conference Coverage: Optimizing the Holistic Health of Patients with Narcolepsy and IH: Meetings to Make Heart and Health Connections

This activity is supported by an educational grant from Lilly.

Meet the Faculty:

Richard K. Bogan MD, FCCP, FAASM
Associate Clinical Professor
University of South Carolina School of Medicine
Principal, Bogan Sleep Consultants, LLC
Columbia, SC

Introduction:

April 6, 2025:

Abstracts:

AXS-12 for the Treatment of Narcolepsy: Topline Results from the Phase 3 SYMPHONY Trial

Narcolepsy & Idiopathic Hypersomnia Patient Journey, Clinical Features and Treatments in a Real-World US Population

Samelisant (SUVN-G3031): Positive Results from Phase-2 Proof-of-concept, Double-blind, Placebo-controlled Study in Patients with Narcolepsy and an Update on Further Clinical Development

April 8, 2025:

Abstracts:

Self-Reported Cognitive Complaints and Work Productivity in Participants With Narcolepsy or Idiopathic Hypersomnia After Low-Sodium Oxybate Treatment: Results From the Phase 4 DUET Study

The Orexin 2 Receptor Agonist ALKS 2680 in Patients with Narcolepsy Type 1: An Initial Proof of Concept Phase 1b Study

CRESCENDO: Results from a Survey of Symptom Burden and Quality of Life in Patients with Narcolepsy Type 1

Patient Preferences of Sodium Oxybate Treatment for Narcolepsy: RESTORE End-of-Study Survey Data

Development of a Novel Patient-reported Outcome Measure of Functional Impacts for Narcolepsy Types 1 and 2

Effectiveness and Safety of Low-Sodium Oxybate in Participants With Narcolepsy or Idiopathic Hypersomnia: Top-line Results From the Phase 4 DUET Study

April 9th, 2025:

Abstracts:

Efficacy and Safety of Low-Sodium Oxybate in Narcolepsy Patients With/Without Psychiatric/Neurologic Comorbidities

Efficacy and Safety of TAK-861, an Oral Orexin Receptor 2 Agonist, in Individuals with Narcolepsy Type 1: Results from a Phase 2 Trial and Long-Term Extension Study Interim Analysis

Establishing Psychometric Evidence of the Novel Patient-reported Functional Impacts of Narcolepsy Instrument (FINI) Using Data from Observational and Phase 2 Clinical Trials in Narcolepsy